MAI Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

MAI Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.5M	Sell	34,731 -3,229	-9%	-$437K	0.02%	458
2026 Q1	$4.85M	Buy	37,960 +941	+3%	+$117K	0.03%	416
2025 Q4	$4.51M	Buy	37,019 +236	+0.6%	+$27.1K	0.03%	415
2025 Q3	$3.69M	Sell	36,783 -1,837	-5%	-$165K	0.02%	427
2025 Q2	$3.2M	Buy	38,620 +31,995	+483%	+$2.55M	0.02%	406
2025 Q1	$537K	Buy	6,625 +386	+6%	+$34.5K	﹤0.01%	799
2024 Q4	$562K	Buy	6,239 +32	+0.5%	+$3.1K	﹤0.01%	809
2024 Q3	$613K	Sell	6,207 -79	-1%	-$7.76K	0.01%	688
2024 Q2	$583K	Buy	6,286 +153	+2%	+$13.7K	0.01%	762
2024 Q1	$582K	Sell	6,133 -622	-9%	-$57.7K	0.01%	742
2023 Q4	$603K	Sell	6,755 -2,052	-23%	-$152K	0.01%	634
2023 Q3	$643K	Sell	8,807 -444	-5%	-$35.5K	0.01%	554
2023 Q2	$770K	Sell	9,251 -5,678	-38%	-$475K	0.01%	493
2023 Q1	$1.14M	Sell	14,929 -3,603	-19%	-$299K	0.02%	397
2022 Q4	$1.54M	Sell	18,532 -825	-4%	-$66.8K	0.03%	332
2022 Q3	$1.53M	Sell	19,357 -253	-1%	-$21.3K	0.03%	309
2022 Q2	$1.46M	Buy	19,610 +6,642	+51%	+$499K	0.03%	313
2022 Q1	$1.17M	Sell	12,968 -101	-0.8%	-$9.33K	0.02%	367
2021 Q4	$1.46M	Buy	13,069 +975	+8%	+$118K	0.02%	346
2021 Q3	$1.52M	Buy	12,094 +503	+4%	+$64.8K	0.03%	287
2021 Q2	$1.57M	Sell	11,591 -320	-3%	-$42.1K	0.03%	275
2021 Q1	$1.62M	Buy	11,911 +209	+2%	+$31.3K	0.04%	256
2020 Q4	$1.65M	Hold	11,702	–	–	0.04%	227
2020 Q3	$1.3M	Sell	11,702 -1,715	-13%	-$192K	0.04%	232
2020 Q2	$1.5M	Buy	13,417 +3,040	+29%	+$299K	0.05%	203
2020 Q1	$804K	Sell	10,377 -13	-0.1%	-$1.15K	0.03%	287
2019 Q4	$988K	Sell	10,390 -2,665	-20%	-$231K	0.03%	284
2019 Q3	$995K	Sell	13,055 -60	-0.5%	-$4.99K	0.04%	238
2019 Q2	$1.15M	Sell	13,115 -2,516	-16%	-$215K	0.05%	228
2019 Q1	$1.42M	Sell	15,631 -2,507	-14%	-$213K	0.07%	182
2018 Q4	$1.3M	Sell	18,138 -1,379	-7%	-$111K	0.08%	188
2018 Q3	$1.87M	Buy	19,517 +1	+0%	+$97	0.1%	163
2018 Q2	$1.86M	Buy	19,516 +426	+2%	+$39.2K	0.1%	163
2018 Q1	$1.68M	Sell	19,090 -66	-0.3%	-$6.03K	0.1%	170
2017 Q4	$1.63M	Buy	19,156 +126	+0.7%	+$10.6K	0.09%	171
2017 Q3	$1.65M	Buy	19,030 +300	+2%	+$24.1K	0.1%	156
2017 Q2	$1.45M	Buy	18,730 +1,025	+6%	+$72.7K	0.09%	165
2017 Q1	$1.23M	Buy	+17,705	New	+$1.19M	0.08%	174
2015 Q3	–	Sell	-2,490	Closed	-$209K	–	473
2015 Q2	$209K	Buy	+2,490	New	+$194K	0.01%	449

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

MAI Capital Management's XBI Position: Q2 2026 in Review

MAI Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 8.5% in Q2 2026, selling an estimated $437K and leaving 34,731 shares worth $5.5M. The position accounts for 0.02% of the portfolio, ranked #458.

MAI Capital Management first reported a position in XBI in Q2 2015 and has held it in 39 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

MAI Capital Management held 34,731 shares of State Street SPDR S&P Biotech ETF worth $5.5M as of Q2 2026.
MAI Capital Management sold 3,229 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $437K.
State Street SPDR S&P Biotech ETF made up 0.02% of MAI Capital Management's portfolio in Q2 2026, its #458 holding.
MAI Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and has held it in 39 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.